Meet the Sebela Pharmaceuticals Team
Alan Cooke serves as Sebela Pharmaceutical’s Chief Executive Officer and President. Prior to joining Sebela Pharmaceuticals, Mr. Cooke held a number of executive level positions primarily in pharmaceuticals and medical devices including Chief Financial Officer and subsequently Chief Executive Officer of Trulife Group Limited; Chief Financial Officer and subsequently President and Chief Operating Officer of Amarin Corporation, plc; and Vice President, Global Strategic Planning of Elan Corporation, plc.
Mr. Cooke is a fellow of the Institute of Chartered Accountants (Ireland) having qualified with KPMG in 1994. Mr. Cooke also currently serves as Chairman of the Board of the Institute of Neuroscience at Trinity College Dublin and as a Director of DS Biopharma Limited.
Paraic McDonogh serves as group Chief Financial Officer. Prior to Sebela Pharmaceuticals, Mr. McDonogh was the Global Finance Director and CFO for Global Consolidated Aesthetic. Mr. McDonogh has also held senior level finance positions at Wellman International and KPMG.
Mr. McDonogh is a Fellow of the Institute of Chartered Accountants in Ireland, and is a graduate of the National University of Ireland Galway.
Scott Briggs serves as Chief Commercial Officer. Mr. Briggs has over 20 years’ experience in pharmaceutical marketing and sales, strategic planning and business management. Prior to Sebela Pharmaceuticals, Mr. Briggs served as Vice President, Marketing and Sales at Noven Pharmaceuticals, where he led commercial operations. Previously, he also served Noven in roles of Vice President – Women’s Health Sales, and as Noven’s Executive Director – Marketing and Managed Markets. Prior to joining Noven, Mr. Briggs was Senior Director of Marketing for JDS Pharmaceuticals. He also has held leadership positions in management and marketing with Ortho-McNeil Pharmaceutical (part of Johnson and Johnson).
Mr. Briggs holds a Bachelor of Arts in Business Administration from Villanova University.
Autumn Akin serves as Vice President of Commercial Affairs. Prior to Sebela Pharmaceuticals, from 2003 to 2010, Ms. Akin held a wide range of positions at Alaven Pharmaceuticals including Territory Business Manager, District Sales Manager, Product Manager and Director of Marketing. Ms. Akin started her pharmaceutical career at First Horizon Pharmaceutical (now Shionogi) where she was a sales representative and later promoted to National Sales Trainer.
Ms. Akin holds a B.B.A in Finance from the University of Georgia.
Jai Wall serves as Vice President, Corporate Affairs. Prior to Sebela Pharmaceuticals, Mr. Wall served as Director of Marketing and Pediatric/Dermatology Sales at Arbor Pharmaceuticals, Inc. He also held the position of VP, Commercial Operations at Meda Pharmaceuticals US after its acquisition of Alaven Pharmaceuticals where he ran the Marketing department. Prior to Alaven, Mr. Wall has held a number of positions with Solvay, both in the US and in the corporate headquarters in Belgium, at Abbott Laboratories and was one of the first employees at ZS Associates.
Mr. Wall holds a B.S. in Industrial Engineering from Northwestern University and an MBA from Duke University.
Stuart Sedlack serves as Vice President, Business Development. He has over 20 years of experience in the pharmaceutical industry, leading corporate business development and closing numerous transactions. Prior to Sebela Pharmaceuticals, Mr. Sedlack was SVP, Corporate Development at Velocity Pharmaceutical Development, Amarin Pharma and Alba Therapeutics, serving as a member of the executive team at each company. Mr. Sedlack also headed transaction negotiations for Novartis Pharma’s infectious disease franchise and was VP, Corporate Development at Elan Corporation after serving as Director at the University of Maryland Medical System’s tech transfer office. Before entering the pharma industry, Mr. Sedlack spent five years in international trade banking.
Mr. Sedlack holds a B.S. in Economics from the University of Richmond and a MBA from Babson College.
Dr. Sue Hall serves as Chief Scientific Officer and Head of Research & Development. Dr. Hall has over 30 years’ of international experience in pharmaceutical research and development. Prior to Sebela Pharmaceuticals, Dr. Hall served as EVP, Chief Scientific Officer and Global Head of R&D for Endo Pharmaceuticals with responsibility for the R&D pipeline and life cycle management for the marketed products portfolio of medicines, as well as overall responsibility for the company’s quality assurance activities. Previously, Dr. Hall also served as SVP and Global Head of R&D for Valeant Pharmaceuticals. Dr. Hall also held several R&D leadership positions at GlaxoSmithKline, including clinical pharmacology, project management, medical affairs, and regulatory affairs.
Dr. Hall holds a Ph.D. in Pharmacokinetics from the University of Manchester, U.K., and a Bachelor of Science in Pharmacology from University of Leeds, U.K.
Medical and Scientific Advisors
Sebela Pharmaceuticals is pleased to have the scientific advisory support of the following leading industry professionals:
John Devane, PhD
John Devane serves as a medical and scientific advisor to Sebela Pharmaceuticals. Prior to Sebela Pharmaceuticals, from 2003 to 2012, Dr. Devane founded and served as the Chief Executive Officer of AGI Therapeutics. From 2001 to 2005, Dr. Devane was the founder and CEO of Athpharma Limited. From 1981 to 2001, Dr. Devane worked at Elan Corporation, where he served in several roles including Executive Vice President R&D (Drug Delivery), Vice President R&D, Vice President Regulatory & Clinical Affairs (USA) and Director, Product Development.
Dr. Devane holds a BSc and a PhD in pharmacology from the University College Dublin.
Virinder Nohria, MD, PhD
Virinder Nohria serves as a medical and scientific advisor to Sebela Pharmaceuticals. Prior to working with Sebela Pharmaceuticals, from 2003 to 2010, Dr. Nohria was the Chief Medical Officer, Chief Compliance Officer and Executive Vice President of Alaven Pharmaceutical, a company he co-founded. As a board-certified neurologist with special qualifications in child neurology, Dr. Nohria is an experienced physician, and with a track record of several NDAs and MAAs, he is a successful biotechnology entrepreneur and drug developer.
Dr. Nohria obtained his MD from the University of Cambridge in England and completed postgraduate training at Duke University. He holds a PhD in Neuropharmacology from the University of Bradford in UK.